Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?



Rating:

Share or cite this content

Citations should be made in the following way:
D. Singh (Manchester, United Kingdom). What is the scientific and clinical rationale? Triple therapy in COPD patients. Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?

Member's Comments

No comment yet.

Related content which might interest you: Clinical effectiveness of triple therapy in the management of COPD: A systematic review Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD Year: 2010 Triple therapy trials in COPD: a precision medicine opportunity Source: Eur Respir J, 52 (6) 1801848; 10.1183/13993003.01848-2018 Year: 2018 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 Triple therapy in COPD: Oportunities and challenges Source: Short Video Statement 2020 Year: 2020 Anti-IgE therapy: rationale and clinical evidence Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives Year: 2007 Guidelines versus clinical practice in the treatment of COPD: a reappraisal Source: Eur Respir J 2006; 27: 656 Year: 2006 Rational monitoring of COPD: where do current clinical guidelines stand? Source: Eur Respir J 2007; 29: 1078-1081 Year: 2007 Revising our approach to conducting therapeutic clinical research in COPD Source: Eur Respir J, 51 (2) 1702712; 10.1183/13993003.02712-2017 Year: 2018 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 The concept of control in COPD: a new proposal for optimising therapy Source: Eur Respir J 2014; 44: 1072-1075 Year: 2014 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 Prescriptions for treatment in patients with PCD: does clinical routine match recommendations? Source: Virtual Congress 2020 – Worldwide respiratory disease across the full spectrum Year: 2020 Emerging concepts in outcome assessment for COPD clinical trials Source: Annual Congress 2007 - PG13 - Outcome measures of clinical trials for new drugs for respiratory disease Year: 2007 Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006 How often do asthma patients claim prescribed therapy? Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS Year: 2017